Lycium barbarum glycopeptide alleviates diabetic retinopathy and hepatic lipid disorder via modulation of the LXR-α/ABC transporter axis - PubMed
2 days ago
- #Traditional medicine
- #Diabetic retinopathy
- #Lipid metabolism
- Lycium barbarum glycopeptide (LbGp) alleviates diabetic retinopathy (DR) and hepatic lipid disorders in db/db mice by modulating the LXR-α/ABC transporter pathway.
- LbGp intervention improved retinal structure, increased thickness of inner nuclear and photoreceptor layers, and restored blood-retinal barrier integrity by enhancing tight junction proteins like Claudin-1 and Occludin.
- The glycopeptide ameliorated dyslipidemia, serum cholestasis, and hepatic injury, with multi-omics analysis showing modulation of fatty acid metabolism, unsaturated fatty acid biosynthesis, and ABC transporters.
- Mechanistically, LbGp upregulated LXR-α, ABCA1, ABCG1, CYP7A1, CYP8B1, and ABCG2, enhancing cholesterol transport and conversion, increasing HDL-C and apoA-I, and reducing LDL-C and harmful cholesterol deposits.